Amifampridine Phosphate
( DrugBank: Amifampridine, Phosphate / KEGG DRUG: Amifampridine )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 3 | Spinal muscular atrophy | 4 |
| 11 | Myasthenia gravis | 4 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 12 | Congenital myasthenic syndrome | 1 |
3. Spinal muscular atrophy
Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
11. Myasthenia gravis
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
12. Congenital myasthenic syndrome
Clinical trials : 5 / Drugs : 7 - (DrugBank : 3) / Drug target genes : 5 - Drug target pathways : 13
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|